What is known about the effects of exercise or training to reduce skeletal muscle impairments of patients with myotonic dystrophy type 1? A scoping review.
Exercise
Muscle atrophy
Muscle weakness
Myotonic dystrophy type 1
Rehabilitation interventions
Training program
Journal
BMC musculoskeletal disorders
ISSN: 1471-2474
Titre abrégé: BMC Musculoskelet Disord
Pays: England
ID NLM: 100968565
Informations de publication
Date de publication:
05 Mar 2019
05 Mar 2019
Historique:
received:
08
08
2018
accepted:
06
02
2019
entrez:
7
3
2019
pubmed:
7
3
2019
medline:
20
6
2019
Statut:
epublish
Résumé
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystemic involvements including a progressive loss of maximal muscle strength and muscle wasting. Poor lower-limb strength is an important factor explaining disrupted social participation of affected individuals. This review aims to map what is known about the effects of exercise and training programs undertaken to counteract skeletal muscle impairments in DM1 patients. Medline, CINAHL and EMBASE databases were searched. Regarding study eligibility, title and abstract of 704 studies followed by 45 full articles were reviewed according to the following eligibility criteria. Inclusion: (1) humans with DM1 and (2) experimental protocol relying on exercise or training. Exclusion: (1) studies that do not evaluate skeletal muscle responses or adaptations, (2) reviews covering articles already included and (3) pharmacological intervention at the same time of exercise or training program. Twenty-one papers were selected for in-depth analysis. Different exercise or training protocols were found including: acute exercise, neuromuscular electric stimulation, strength training, aerobic training, balance training and multiple rehabilitation interventions. Seven studies reported clinical measurements only, five physiological parameters only and nine both types. This scoping review offers a complete summary of the current scientific literature on the effect of exercise and training in DM1 and a framework for future studies based on the concomitant evaluation of the several outcomes in present literature. Although there were a good number of studies focusing on clinical measurements, heterogeneity between studies does not allow to identify what are the adequate training parameters to obtain exercise or training-induced positive impacts on muscle function. Scientific literature is even more scarce regarding physiological parameters, where much more research is needed to understand the underlying mechanisms of exercise response in DM1.
Sections du résumé
BACKGROUND
BACKGROUND
Myotonic dystrophy type 1 (DM1) is a neuromuscular disease characterized by multisystemic involvements including a progressive loss of maximal muscle strength and muscle wasting. Poor lower-limb strength is an important factor explaining disrupted social participation of affected individuals. This review aims to map what is known about the effects of exercise and training programs undertaken to counteract skeletal muscle impairments in DM1 patients.
METHODS
METHODS
Medline, CINAHL and EMBASE databases were searched. Regarding study eligibility, title and abstract of 704 studies followed by 45 full articles were reviewed according to the following eligibility criteria. Inclusion: (1) humans with DM1 and (2) experimental protocol relying on exercise or training. Exclusion: (1) studies that do not evaluate skeletal muscle responses or adaptations, (2) reviews covering articles already included and (3) pharmacological intervention at the same time of exercise or training program.
RESULTS
RESULTS
Twenty-one papers were selected for in-depth analysis. Different exercise or training protocols were found including: acute exercise, neuromuscular electric stimulation, strength training, aerobic training, balance training and multiple rehabilitation interventions. Seven studies reported clinical measurements only, five physiological parameters only and nine both types.
CONCLUSION
CONCLUSIONS
This scoping review offers a complete summary of the current scientific literature on the effect of exercise and training in DM1 and a framework for future studies based on the concomitant evaluation of the several outcomes in present literature. Although there were a good number of studies focusing on clinical measurements, heterogeneity between studies does not allow to identify what are the adequate training parameters to obtain exercise or training-induced positive impacts on muscle function. Scientific literature is even more scarce regarding physiological parameters, where much more research is needed to understand the underlying mechanisms of exercise response in DM1.
Identifiants
pubmed: 30836978
doi: 10.1186/s12891-019-2458-7
pii: 10.1186/s12891-019-2458-7
pmc: PMC6402179
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Subventions
Organisme : Fonds de Recherche du Québec - Santé (CA)
ID : N/A
Organisme : Canadian Institutes of Health Research
ID : N/A
Pays : Canada
Organisme : Fondation du grand défi Pierre Lavoie
ID : N/A
Organisme : Corporation de recherche et d'action sur les maladies héréditaires
ID : N/A
Organisme : Fondation de l'Université du Québec à Chicoutimi
ID : N/A
Organisme : Fonds de Recherche du Québec - Santé
ID : 31011
Commentaires et corrections
Type : ErratumIn
Références
Biochim Biophys Acta. 1999 Feb 24;1453(2):221-9
pubmed: 10036320
Scand J Rehabil Med. 1999 Mar;31(1):9-16
pubmed: 10229998
Diabetes. 1999 May;48(5):1108-12
pubmed: 10331417
Physiother Res Int. 1999;4(1):1-11
pubmed: 10368835
J Electromyogr Kinesiol. 1999 Dec;9(6):379-84
pubmed: 10597050
Neurology. 2001 Feb 13;56(3):336-40
pubmed: 11171898
Hum Mol Genet. 2001 Sep 15;10(19):2079-87
pubmed: 11590125
Neuromuscul Disord. 2001 Nov;11(8):728-35
pubmed: 11595515
Brain Res Bull. 2001 Oct-Nov 1;56(3-4):405-10
pubmed: 11719279
Arch Phys Med Rehabil. 2002 May;83(5):724-6
pubmed: 11994815
Science. 1992 Mar 6;255(5049):1256-8
pubmed: 1546326
Ann Neurol. 2005 May;57(5):754-7
pubmed: 15852373
Occup Ther Int. 2005;12(1):14-27
pubmed: 15962697
Ann Neurol. 2006 May;59(5):871-2
pubmed: 16634010
J Biol Chem. 2008 Aug 15;283(33):22457-63
pubmed: 18559347
Arch Phys Med Rehabil. 2008 Jul;89(7):1246-55
pubmed: 18586127
Mol Genet Metab. 2009 Jan;96(1):20-6
pubmed: 19013090
Am J Pathol. 2009 Apr;174(4):1435-42
pubmed: 19246640
BMJ. 2009 Jul 21;339:b2535
pubmed: 19622551
Int J Pediatr Otorhinolaryngol. 2010 Oct;74(10):1126-34
pubmed: 20638139
Ann Phys Rehabil Med. 2010 Aug-Sep;53(6-7):387-98
pubmed: 20638922
Folia Morphol (Warsz). 2011 May;70(2):121-9
pubmed: 21630234
J Rehabil Med. 2011 Jul;43(8):695-702
pubmed: 21670942
J Clin Invest. 2012 Dec;122(12):4461-72
pubmed: 23160194
Disabil Rehabil. 2013 Oct;35(21):1798-807
pubmed: 23480644
Cochrane Database Syst Rev. 2013 Jul 09;(7):CD003907
pubmed: 23835682
J Neuroeng Rehabil. 2013 Aug 12;10:94
pubmed: 23938156
Ann Neurol. 1986 Nov;20(5):590-6
pubmed: 2431651
Acta Myol. 2013 Dec;32(3):154-65
pubmed: 24803843
Muscle Nerve. 2015 Apr;51(4):473-8
pubmed: 25399769
Front Aging Neurosci. 2015 Jul 09;7:125
pubmed: 26217220
BMC Neurol. 2015 Aug 22;15:148
pubmed: 26296336
Am J Phys Med Rehabil. 2016 Nov;95(11):809-817
pubmed: 27088471
Rev Neurol (Paris). 2016 Oct;172(10):572-580
pubmed: 27665240
Muscle Nerve. 2017 Jul;56(1):57-63
pubmed: 27784130
Eur J Appl Physiol. 2017 Mar;117(3):551-566
pubmed: 28194519
Hum Mol Genet. 2017 Jun 15;26(12):2192-2206
pubmed: 28369518
J Neurol. 2018 Jul;265(7):1698-1705
pubmed: 29785524
J Physiol. 2019 Mar;597(5):1361-1381
pubmed: 30628727
Ann Neurol. 1985 Jan;17(1):65-9
pubmed: 3985589
J Neurol Sci. 1985 Mar;67(3):299-306
pubmed: 3989573
J Neurol Sci. 1983 Jul;60(1):157-68
pubmed: 6875612
Arch Phys Med Rehabil. 1995 Jul;76(7):612-20
pubmed: 7605179
J Neurol Sci. 1993 Jun;116(2):193-200
pubmed: 8336166
Muscle Nerve. 1997 Feb;20(2):232-4
pubmed: 9040665
Brain. 1997 Oct;120 ( Pt 10):1699-711
pubmed: 9365364
J Biol Chem. 1997 Nov 21;272(47):29626-35
pubmed: 9368029